DaVita®, a division of DaVita HealthCare Partners Inc. (NYSE: DVA) and a leading provider of kidney care services, today announced a partnership with one of Germany’s most renowned nephrology practices to deliver leading renal care to patients in Düsseldorf. Praxis mit Nähe joins DaVita along with its world-class physicians including Prof. Werner Kleophas, Dr. Andreas Westhoff, Prof. Gerd Hetzel and Prof. Frank Dellanna. “The addition of this highly regarded practice is an exciting opportunity for DaVita and represents a key step in our long-term growth strategy in Europe,” said Dennis Kogod, chief operating officer of DaVita HealthCare Partners SM. “DaVita brings a model to Germany that wonderfully aligns with the values our practice has held for more than 30 years,” said Prof. Werner Kleophas. “Being product independent, DaVita’s sole focus is on perfection in kidney care delivery and putting patients first. We’ve always cherished independence and liberty in treatment and together with DaVita we believe we can accomplish great results in the delivery of care for our patients in Düsseldorf.” Praxis mit Nähe has six Düsseldorf-based clinics specializing in dialysis, nephrology and diabetology and was one of the largest privately held groups in Germany. The partnership more than doubles DaVita’s footprint in Germany with a current total number of ten centers. “When DaVita entered Germany two years ago, our aim was to improve quality of life for the country’s kidney care patients,” said Bjӧrn Englund, president of DaVita’s Europe and Middle East operations. “Having these esteemed doctors join DaVita is a testament to the strides we’ve made and positions DaVita as the partner and provider of choice in German kidney care.” DaVita and DaVita HealthCare Partners are trademarks or registered trademarks of DaVita HealthCare Partners Inc. All other trademarks are the property of their respective owners.
About DaVitaDaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of kidney care in the United States, DaVita delivers dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of September 30, 2013, DaVita operated or provided administrative services at 2,042 outpatient dialysis centers located in the United States serving approximately 166,000 patients. The company also operated 67 outpatient dialysis centers located in ten countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit DaVita.com. Forward-Looking Statements This release contains forward-looking statements within the meaning of the federal securities laws, including statements related to anticipated and prospective growth of certain of our international ventures and the clinical outcomes that they will deliver. Factors which could impact future results include the risks and uncertainties associated with expansion of our operations and services to markets outside the United States, including local governmental regulations, general economic and other market conditions, competition, and the other applicable risk factors set forth in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2012, and subsequent quarterly reports filed on Form 10-Q. The forward-looking statements should be considered in light of these risks and uncertainties. We base our forward-looking statements on information currently available to us at the time of this release, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of changes in underlying factors, new information, future events or otherwise.